These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8467871)

  • 21. Selective reduction of N-methyl-D-aspartate-evoked responses by 1,3-di(2-tolyl)guanidine in mouse and rat cultured hippocampal pyramidal neurones.
    Fletcher EJ; Church J; Abdel-Hamid K; MacDonald JF
    Br J Pharmacol; 1993 Aug; 109(4):1196-205. PubMed ID: 8401930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The sigma agonist 1,3-di-o-tolyl-guanidine directly blocks SK channels in dopaminergic neurons and in cell lines.
    Lamy C; Scuvée-Moreau J; Dilly S; Liégeois JF; Seutin V
    Eur J Pharmacol; 2010 Sep; 641(1):23-8. PubMed ID: 20546722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats.
    Skuza G; Rogóz Z
    Pol J Pharmacol; 2003; 55(6):1149-52. PubMed ID: 14730114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,3-Di(2-[5-3H]tolyl)guanidine labels more than one site in rat forebrain.
    Codd EE; Shank RP
    Eur J Pharmacol; 1992 Jul; 217(2-3):149-52. PubMed ID: 1425936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism.
    Matsumoto RR; Bowen WD; Tom MA; Vo VN; Truong DD; De Costa BR
    Eur J Pharmacol; 1995 Jul; 280(3):301-10. PubMed ID: 8566098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uncompetitive inhibition of [3H]1,3-di-o-tolyl-guanidine-defined sigma binding sites by desipramine, propranolol and alprenolol in rat brain.
    Shirayama Y; Takahashi K; Nishikawa T
    Eur J Pharmacol; 1997 Jul; 331(2-3):319-23. PubMed ID: 9274995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of 1,3-di(2-[5-3H]tolyl) guanidine with sigma 2 binding sites in rat heart membrane preparations.
    Dumont M; Lemaire S
    Eur J Pharmacol; 1991 Dec; 209(3):245-8. PubMed ID: 1665796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of specific (+)-[3H]N-allylnormetazocine and [3H]1,3-di(2-tolyl)guanidine binding sites in porcine gastric fundic mucosa.
    Harada Y; Hara H; Sukamoto T
    J Pharmacol Exp Ther; 1994 Jun; 269(3):905-10. PubMed ID: 8014877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of (+)-pentazocine and 1,3-di-o-tolylguanidine (DTG), sigma (sigma) ligands, on micturition in anaesthetized rats.
    Shimizu I; Kawashima K; Ishii D; Oka M
    Br J Pharmacol; 2000 Oct; 131(3):610-6. PubMed ID: 11015314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of σ-receptors induces binge-like drinking in Sardinian alcohol-preferring rats.
    Sabino V; Cottone P; Blasio A; Iyer MR; Steardo L; Rice KC; Conti B; Koob GF; Zorrilla EP
    Neuropsychopharmacology; 2011 May; 36(6):1207-18. PubMed ID: 21346735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sigma binding parameters in developing rats predict behavioral efficacy of a sigma ligand.
    Hemstreet MK; Matsumoto RR; Bowen WD; Walker JM
    Brain Res; 1993 Nov; 627(2):291-8. PubMed ID: 8298974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of cytochrome P-450 induction on ligand binding to sigma receptors.
    Basile AS; Paul IA; de Costa B
    Eur J Pharmacol; 1992 Sep; 227(1):95-8. PubMed ID: 1426026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands.
    Rothman RB; Reid A; Mahboubi A; Kim CH; De Costa BR; Jacobson AE; Rice KC
    Mol Pharmacol; 1991 Feb; 39(2):222-32. PubMed ID: 1847495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of subcutaneous and intracerebroventricular administration of the sigma receptor ligand 1,3-Di-o-tolylguanidine on body temperature in the rat: interactions with BMY 14802 and rimcazole.
    Bejanian M; Pechnick RN; Bova MP; George R
    J Pharmacol Exp Ther; 1991 Jul; 258(1):88-93. PubMed ID: 1677044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of haloperidol-sensitive sigma-sites in antitussive effects.
    Kamei J; Iwamoto Y; Kawashima N; Hitosugi H; Misawa M; Kasuya Y
    Eur J Pharmacol; 1992 Nov; 224(1):39-43. PubMed ID: 1451741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Competitive and non-competitive NMDA receptor antagonists in spatial learning tasks.
    Bischoff C; Tiedtke PI
    Eur J Pharmacol; 1992 Mar; 213(2):269-73. PubMed ID: 1355738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discrepancies in characterization of sigma sites in the mouse central nervous system.
    Kovács KJ; Larson AA
    Eur J Pharmacol; 1995 Oct; 285(2):127-34. PubMed ID: 8566130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain.
    Itzhak Y; Ali SF
    Ann N Y Acad Sci; 1998 May; 844():245-51. PubMed ID: 9668682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1,3-Di(2-tolyl)guanidine blocks nicotinic response in guinea pig myenteric neurons.
    Galligan JJ; Campbell BG; Kavanaugh MP; Weber E; North RA
    J Pharmacol Exp Ther; 1989 Oct; 251(1):169-74. PubMed ID: 2552073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of short-term and long-term treatments with sigma ligands on the N-methyl-D-aspartate response in the CA3 region of the rat dorsal hippocampus.
    Bergeron R; de Montigny C; Debonnel G
    Br J Pharmacol; 1997 Apr; 120(7):1351-9. PubMed ID: 9105712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.